 |
236 Diseases |  |
41 Trials |
|
41 Trials |  |
3914 News |  |
| «12...2526272829303132333435...4849» |
- | Tykerb (lapatinib) / Novartis
Biomarker, Journal: Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells. (Pubmed Central) - Jan 29, 2020
Thy1-low cells with increased EGFR and Notch1 expression are responsive to target therapy. Because DNA methylation is often altered in early cancer development, candidate methylation markers may be exploited as biomarkers for basal-like breast cancer.
- | Tykerb (lapatinib) / Novartis
Preclinical, Journal: Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line. (Pubmed Central) - Jan 28, 2020
However, laptinib reduced the EGFR protein expression and EGFR signals, it raised the apoptotic cells and TP53 gene signals, which triggered extensive DNA damage. Therefore, lapatinib is an effective TKI in triple negative breast cancer cells as elucidated by its mode of cell death.
- | Tykerb (lapatinib) / Novartis
Journal: An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway. (Pubmed Central) - Jan 26, 2020
Altogether, we discovered a procarcinogenic mutation of ERBB2 that enhances BC cell growth through AKT signaling and causes resistance to lapatinib. Patients with this in-frame insertion mutation of ERBB2 should be recommended other therapeutic strategies apart from ERBB2 tyrosine kinase inhibitors, in particular lapatinib.
- Routine Care Reality of Patients with Metastatic Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Received Treatment in Oncology Group Practices in Germany Between 2012 and 2017 (atrium) - Jan 25, 2020 - Abstract #DKK2020DKK_2351;
1st line Anti HER2 therapy consisted of trastuzumab+pertuzumab in 54%, trastuzumab in 36%, lapatinib in 5% and trastuzumab emtansine in 4%. OS improvements of patients with metastatic HER2 positive breast cancer are strongly restricted to hormone receptor positive tumors most likely due to improved targeted therapies directed against HER2 and the estrogen receptor.
- Tykerb (lapatinib) / Novartis, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, capecitabine / Generic mfg.
Neratinib + Capecitabine Versus Lapatinib + Capecitabine in Patients with HER2+ Metastatic Breast Cancer Previously Treated with ≥ 2 HER2-Directed Regimens: The Multinational, Randomized, Phase III Trial Nala (Room A2) - Jan 25, 2020 - Abstract #DKK2020DKK_2053;
P3
N+C resulted in a reduced incidence of interventions for CNS progression compared to L+C. No new safety signals were observed.
- | Vizimpro (dacomitinib) / Pfizer
Preclinical, Journal: Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability. (Pubmed Central) - Jan 21, 2020
Such values infer that DMB would be excreted very slowly from the human body, which might lead to possible bioaccumulation. To the best of our knowledge, this is the first method for DMB analysis in RLMs with metabolic stability estimation.
- | Herceptin (trastuzumab) / Roche
Trial completion date: CTRIAL-IE (ICORG) 11-10: A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Jan 21, 2020
P3, N=75, Active, not recruiting, Sponsor: Cancer Trials Ireland
To the best of our knowledge, this is the first method for DMB analysis in RLMs with metabolic stability estimation. Trial completion date: Dec 2018 --> Dec 2021
- Tykerb (lapatinib) / Novartis, Herceptin (trastuzumab) / Roche
Real-World data of triplet combination of trastuzumab, lapatinib and chemotherapy in HER2-positive metastatic breast cancer: a multi-center retrospective study (Poster Area/Exhibition Hall) - Jan 19, 2020 - Abstract #EBCC2020EBCC_413;
Trial completion date: Dec 2018 --> Dec 2021 Abstract will be shown 2 weeks before the conference (with consent of the author)
- || Review, Journal: Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. (Pubmed Central) - Jan 18, 2020
The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial...In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors.
- | Tykerb (lapatinib) / Novartis, Rydapt (midostaurin) / Novartis
Biomarker, Journal: A Stemness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer. (Pubmed Central) - Jan 18, 2020
It can be used to trace tumor cells during the course of phenotypic changes they undergo, that result in altered responses to therapeutic agents. The fact that such a list cannot be used to identify prognosis in most patient cohorts suggests that presence of factors other than stemness and EMT affect mortality.
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche
Biomarker, Journal: Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5. (Pubmed Central) - Jan 17, 2020
P=N/A
Sunitinib is standard care for metastatic renal cell carcinomas (mRCC) and lapatinib is used for trastuzumab/pertuzumab-refractory cancers...The levels of CXCL5 present in the plasma of patients treated with sunitinib were predictive of the efficacy of sunitinib but not of the VEGF-directed antibody bevacizumab. This translational study identified CXCL5 as a biomarker of efficacy of lysosomotropic drugs, a potential asset for personalized medicine.
- | Tykerb (lapatinib) / Novartis
Journal: Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumour activity as EGFR-TK inhibitor. (Pubmed Central) - Jan 15, 2020
Molecular docking showed that compound 6a formed three hydrogen bonds with EGFR-TK, while lapatinib formed only two hydrogen bonds with the receptor protein. It is believed that this work would be giving a reference for developing anti-cancer drugs targeted EGFR-TK.
- | Tykerb (lapatinib) / Novartis
Journal: Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. (Pubmed Central) - Jan 11, 2020
Thus, lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. An EGFR-targeting therapy could be an important treatment for Cushing's disease.
- | Herceptin (trastuzumab) / Roche, trastuzumab biosimilar / Hetero
Journal: Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. (Pubmed Central) - Jan 11, 2020
An EGFR-targeting therapy could be an important treatment for Cushing's disease. The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.
- ||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Afinitor (everolimus) / Novartis
Retrospective data, Journal, Adverse events: Targeted Tumour Therapy Induced Papulopustular Rash and Other Dermatologic Side Effects: A Retrospective Study. (Pubmed Central) - Jan 11, 2020
With the increasing use of targeted therapies, dermatologists are now confronted with the extensive spectrum of skin toxicities. Therefore, it is critical for dermatologists to be aware of these toxicities so as to develop the best approach without discontinuation of cancer therapy.
- | Biomarker, Review, Journal: HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. (Pubmed Central) - Jan 11, 2020
Therefore, it is critical for dermatologists to be aware of these toxicities so as to develop the best approach without discontinuation of cancer therapy. The future of cardiotoxicity management in patients with HER2+ breast cancer is discussed, with a focus on novel techniques to improve cardiac outcomes, including new imaging modalities, biomarkers, interventional therapies, and ongoing trials.
- | Journal: A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. (Pubmed Central) - Jan 11, 2020
The future of cardiotoxicity management in patients with HER2+ breast cancer is discussed, with a focus on novel techniques to improve cardiac outcomes, including new imaging modalities, biomarkers, interventional therapies, and ongoing trials. Our results highlight that dual inhibition of cdc7 and CDK9 by PHA-767491 is a potential strategy for targeting TNBC resistant to EGFR-TKIs.
- | Tykerb (lapatinib) / Novartis
Preclinical, Journal: Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines. (Pubmed Central) - Jan 10, 2020
Lapatinib exhibited cytotoxic properties on ErbB1/ErbB2 expressing cell lines, with intestinal cells being more sensitive to lapatinib compared to tumour cells. Lapatinib induced necrosis in tumour cells, while inducing late apoptosis in intestinal cells may explain lapatinib-induced diarrhoea in patients administered with the drug which could be due to apoptosis of intestinal epithelial cells leading to barrier disruption and consequently diarrhoea.
- || veliparib (ABT-888) / AbbVie
Trial completion date, Trial primary completion date, PARP Biomarker: Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 8, 2020
P=N/A, N=23, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Lapatinib induced necrosis in tumour cells, while inducing late apoptosis in intestinal cells may explain lapatinib-induced diarrhoea in patients administered with the drug which could be due to apoptosis of intestinal epithelial cells leading to barrier disruption and consequently diarrhoea. Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Dec 2020
- ||| Tykerb (lapatinib) / Novartis, Sutent (sunitinib) / Pfizer
Clinical: Thanks 🙏 @montypal indeed we published on strategy of switch maintenance recently https://t.co/ck6y7SMVAO after many attempts, e.g. lapatinib, sunitinib https://t.co/ocwltQSSrj it seems that we found the optimal mechanism for this! @Uromigos @tompowles1 @OncoAlert @urotoday (Twitter) - Jan 7, 2020
- Tykerb (lapatinib) / Novartis
Phase IIR of CRT +/- Lapatinib in high risk stage III-IV HNSCC (Montgomery/2nd Level) - Jan 7, 2020 - Abstract #NRG2020NRG_594;
- || Herceptin (trastuzumab) / Roche
Biomarker, Trial completion date, Trial primary completion date: Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jan 7, 2020
P2, N=225, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Dec 2020 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- || Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
Trial primary completion date, Metastases: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases (clinicaltrials.gov) - Jan 7, 2020
P2, N=228, Recruiting, Sponsor: RemeGen
Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020 Trial primary completion date: Dec 2019 --> Jul 2020
- || Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche
Clinical, Review, Journal: Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors. (Pubmed Central) - Jan 2, 2020
There is insufficient evidence to make recommendations regarding: the use of epidermal growth factor receptor inhibitors erlotinib and gefitinib in patients with brain metastasis due to nonsmall cell lung cancerthe use of BRAF inhibitors dabrafenib and vemurafenib in the treatment of patients with brain metastases due to metastatic melanomathe use of HER2 agents trastuzumab and lapatinib to treat patients with brain metastases due to metastatic breast cancerthe use of vascular endothelial growth factor agents bevacizumab, sunitinib, and sorafenib in the treatment of patients with solid tumor brain metastases. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-treatment-adults-metastatic-brain-tumors/chapter_9.
- | Tykerb (lapatinib) / Novartis, Faslodex (fulvestrant) / AstraZeneca
Journal: Triggered Release Enhances the Cytotoxicity of Stable Colloidal Drug Aggregates. (Pubmed Central) - Jan 1, 2020
By stabilizing acid-responsive lapatinib colloids through coaggregation with fulvestrant, and inclusion of transferrin, we demonstrate colloid internalization by cancer cells, where subsequent lapatinib ionization leads to endosomal leakage and increased cytotoxicity. These results demonstrate a strategy for triggered drug release from stable colloidal aggregates.
- | Tykerb (lapatinib) / Novartis, fingolimod / Generic mfg., Nexavar (sorafenib) / Bayer, Amgen
Journal: Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest. (Pubmed Central) - Dec 25, 2019
The enhancement of ER stress loading and cell cycle arrest induced by combined treatment with Lap or Sor and FTY720, which was associated with the cytotoxicity induced by the combination of these drugs. These findings suggested that FTY720 improved TKI therapy in NSCLC patients with wild‑type EGFR, by sensitizing NSCLC cells to TKIs.
- ||| Tykerb (lapatinib) / Novartis, Tagrisso (osimertinib) / AstraZeneca
Will Upfront use of drugs with better CNS penetration (Lapatinib/Td-M1/Deruxtecan) akin to Osimertinib in mEGFR lung Ca be a better strategy ? (Twitter) - Dec 24, 2019
- || Tykerb (lapatinib) / Novartis, Herceptin (trastuzumab) / Roche
Clinical, Journal: Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma. (Pubmed Central) - Dec 23, 2019
This approach achieved a partial response for both the brain and the lung metastases. This study demonstrated that HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and, combined with lapatinib, it can effectively target brain metastasis.
- || Herceptin (trastuzumab) / Roche
Clinical, Journal: Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. (Pubmed Central) - Dec 23, 2019
This study demonstrated that HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and, combined with lapatinib, it can effectively target brain metastasis. HER2-positive early breast cancer is characterized by the presence of two diseases with distinct natural history based on HR status requiring the development of different follow-up strategies and future de-escalation and escalation clinical trials.
- | Tykerb (lapatinib) / Novartis
Journal: Theoretical study on the mechanism of N- and α-carbon oxidation of lapatinib catalyzed by cytochrome P450 monooxygenase. (Pubmed Central) - Dec 23, 2019
It is worthy to study subsequent N-hydroxylation and its downstream reaction, which may be the main pathway for the formation of nitroso. These results lay the foundation for drug design and optimization.
- | Tykerb (lapatinib) / Novartis
Journal, Combination therapy: Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma. (Pubmed Central) - Dec 22, 2019
As lapatinib is approved for other oncological indications, a realization of its potential combination with PDT and in fluorescence-guided resection could be readily tested clinically. Furthermore, as its use would only be in acute settings, long-term resistance should not pose an issue as compared to its use as monotherapy.
- || Herceptin (trastuzumab) / Roche
Clinical, Journal, Gene Signature: An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). (Pubmed Central) - Dec 22, 2019
These results indicate RBsig may add valuable information to HER2 and HR expression, which may in turn inform treatment choices. HR+/HER2+/RBsig Low breast cancers exhibited the poorest pathological response following chemotherapy plus H. Accordingly, in such patients, endocrine therapy in combination with H and, possibly, a CDK4/6 inhibitor, may potentially prove to be a more effective treatment.
- | Tarceva (erlotinib) / Astellas, Roche
Preclinical, Journal: Inhibition of ABCB1 and ABCG2 at the mouse blood-brain barrier with marketed drugs to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib. (Pubmed Central) - Dec 21, 2019
Taken together, our data suggest that some marketed tyrosine kinase inhibitors may be repurposed to inhibit ABCB1 and ABCG2 at the BBB. From a clinical perspective, moderate increases in brain delivery despite the administration of high i.v. doses as well as peripheral drug-drug interactions due to transporter inhibition in clearance organs question the translatability of this concept.
- | Journal: Autophagy as a molecular target for cancer treatment. (Pubmed Central) - Dec 20, 2019
In this sense, we also review the shared regulatory pathways that play a role in autophagy and malignant transformation. Finally, anti-cancer therapeutic agents used as either inhibitors or inducers of autophagy have been discussed.
- | Preclinical, Journal: Application of an automated small-scale in vitro transfer model to predict in vivo precipitation inhibition. (Pubmed Central) - Dec 20, 2019
During the transfer model experiments, this intermediate supersaturated state was stabilized using HPMCAS and Soluplus. The PI screening protocol described herein allows to study the effect of PIs for solubility and potential bioavailability improvement of poorly soluble drugs to support formulation development already in early stages.
- | Tykerb (lapatinib) / Novartis
Journal: Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. (Pubmed Central) - Dec 18, 2019
DDAs and TRAIL synergize to kill cancer cells and are cytotoxic to HER2+ cancer cells with acquired resistance to the EGFR/HER2 tyrosine kinase inhibitor Lapatinib...Our results indicate that DDAs are unique in causing DR5 accumulation and oligomerization and inducing downstream caspase activation and cancer cell death through mechanisms involving altered DR5 disulfide bonding. DDAs thus represent a new therapeutic approach to cancer therapy.
- | Herceptin (trastuzumab) / Roche
Trial completion date: Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer (clinicaltrials.gov) - Dec 13, 2019
P2, N=116, Active, not recruiting, Sponsor: Nancy Lin, MD
DDAs thus represent a new therapeutic approach to cancer therapy. Trial completion date: Dec 2019 --> Dec 2020
- || Tykerb (lapatinib) / Novartis
Should This trial had an arm with lapatinib ? (Twitter) - Dec 11, 2019
- ||| Tykerb (lapatinib) / Novartis
I'd vote for lapatinib + tras + cape, the cheaper dual HER2 blockade (Twitter) - Dec 11, 2019
- |||| Tykerb (lapatinib) / Novartis, Herceptin (trastuzumab) / Roche, capecitabine / Generic mfg.
Tucatanib results with 21.9 median OS versus 17.4mo with Xeloda and trastuzumab alone, but how would this have compared to lapatinib? #SABCS2019 (Twitter) - Dec 11, 2019
- ||||| Herceptin (trastuzumab) / Roche
Trial completion: ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib (clinicaltrials.gov) - Dec 11, 2019
P3, N=63, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2019 --> Dec 2020 Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients. (Level 1, West Hall - Poster Board A14) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_777;
Even after excluding known HER2 over-expression and CN gain, PAM50-like gene classifier identifies a far higher than expected percentage of HER-E subtype CRC (99/167 = 59%) which may represent an under appreciated population for HER2 directed therapy and clinical trials. Research Funding: NantHealth
- || Herceptin (trastuzumab) / Roche
Trial completion: Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. (clinicaltrials.gov) - Dec 10, 2019
P1, N=31, Completed, Sponsor: Novartis Pharmaceuticals
Research Funding: NantHealth Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Journal: Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease. (Pubmed Central) - Dec 8, 2019
Therefore, ERBB family inhibitor afatinib was initiated...This is the first report of ERBB2 mutated, metastatic extramammary Paget's disease with secondary resistance to trastuzumab / carboplatin, potentially due to additional acquired genomic alterations. This case contributes to the growing evidence of HER2 in the pathogenesis of metastatic extramammary Paget's disease and emphasizes the importance of repetitive, genomic analysis in rare diseases.
- | Herceptin (trastuzumab) / Roche
Journal: Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma. (Pubmed Central) - Dec 6, 2019
Furthermore, putative HER2-overexpressed cells in ASGC were detected with trastuzumab by flow cytometry. These preliminary data may lead to further evaluation of the role of HER2 in canine ASGC as a mechanism of malignancy and as a therapeutic target for HER2-targeted therapy.
- |||||||||| BAT8001 - Bio / Thera Solutions
New P3 trial, Head-to-Head, Metastases: BAT-8001-002-CR: The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - Dec 3, 2019
P3, N=410, Active, not recruiting, Sponsor: Bio-Thera Solutions
- || Tykerb (lapatinib) / Novartis, Nerlynx (neratinib) / Puma, Knight Therap
When I was on neratinib, I had a horrible time with diarrhea. But I told my onc I was managing it. Well, I was at times but other times....OMG. I did it because I wanted to stay on it as long as possible. I didn’t want to take Tykerb - giant pills - *gag* (Twitter) - Nov 30, 2019
- || Tykerb (lapatinib) / Novartis
Biomarker, Clinical, Journal: Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2-positive gastric cancer patients. (Pubmed Central) - Nov 28, 2019
The follow-up cfDNA genomics at disease progression demonstrated that there are emergences of other genomic aberrations such as MYC, EGFR, FGFR2 and MET amplifications. The present study showed that HER2+ GC patients respond differently according to concomitant genomic aberrations beyond ERBB2, high ERBB2 amplification by NGS or cfDNA can be a positive predictor for patient selection, and tumor genomic alterations change significantly during targeted agent therapy.
- | Journal: Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). (Pubmed Central) - Nov 27, 2019
The present study showed that HER2+ GC patients respond differently according to concomitant genomic aberrations beyond ERBB2, high ERBB2 amplification by NGS or cfDNA can be a positive predictor for patient selection, and tumor genomic alterations change significantly during targeted agent therapy. L-based therapy is an active therapeutic option and remains a viable option for HER2 + MBC after prior trastuzumab, P and/or T-DM1.